Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17272991 | 1.00 | JAK2 (0.34) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL14697426 | 0.89 | JAK2 (0.34) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL15944686 | 0.89 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL14708586 | 0.88 | JAK2 (0.33) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL17350116 | 0.88 | JAK2 (0.33) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL18488786 | 0.88 | JAK2 (0.33) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL17272990 | 0.88 | DGAT1 (0.33) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL16477567 | 0.88 | DGAT1 (0.33) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL17272988 | 0.88 | JAK2 (0.33) | JAK2JAK1TYK2JAK3BRD4 | |
| SCHEMBL14697182 | 0.87 | JAK2 (0.35) | JAK2JAK1TYK2JAK3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385052-B2 | Tricyclic compound and JAK inhibitor | NISSAN CHEMICAL CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| EP-3144309-B1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-20180099966-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-04-12 | — | — | US | disclosed |
| US-9890165-B2 | Tricyclic compound and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9890165-B2 | Tricyclic compound and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| EP-3144309-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170044161-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044161-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044161-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099966-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 11/4885 |
| US-10385052-B2 | Tricyclic compound and JAK inhibitor | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 11/4885 |
| US-20170044161-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885TYK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.